Weekly Coffee Breaks
Thursdays at 09:00 (CEST, Paris)
Fridays at 15:00 (CEST, Paris)
First Thursday of the month – Innovators
Second Thursday of the month – Leaders
Third Thursday of the month – Investments
Therapeutic Spotlight: Cardiology
August 26, 2021
17:00 (CEST, Paris)
Cardiovascular-related diseases are the leading cause of death globally, accounting for over 17 million deaths per year, a number that is expected to grow by 5 million by 2030.
Network around the clinical and biopharma research collaborations, along with the advances in devices and the use of AI in at-risk patients.
Lev Goldin, Director, Business Development & Licensing - Cardiovascular, Metabolism, Endocrinology & Fertility & Commercial, Merck KGaA, will join the session to talk about Merck’s activity in the cardiovascular field.
The most impactful resource: Your team
An interview with Dr Thorsten Genski, CEO
Serengen GmbH, Dortmund, Germany
Choose your founding team wisely. Do not necessarily choose friends because you will argue from time to time. But choose people who you trust and would readily concede that their contributions to the success was more important than yours. In my experience, a lack of trust, mistrust or worse, resentment will cause you to waste time and energy, distract you from the important tasks and most likely lead to failure.
How does the VIC support innovation?
An interview with Aline Charpentier, Head of Innovation Support,
One Nucleus, Cambridge and London, United Kingdom
The VIC is a mix of:
- An annual programme of workshops dedicated to these questions of growing a life science company from an operational, business and strategic perspective.
- Access to bespoke expertise from One Nucleus and the VIC partners.
- Opportunities to grow and raise profiles within the One Nucleus network.
Alkermes: Driving Ambition in the Innovative Neuroscience and Oncology Space
Alkermes has been reimagining medicines to help improve the therapeutic experience for patients for more than 30 years. Its current research and development efforts are focused on the pursuit of potential new medicines that build on the company’s heritage in neuroscience and more recent advancements into immuno-oncology. The 2019 acquisition of Rodin Therapeutics has also expanded Alkermes’ early-stage development efforts into a wider range of neurodegenerative disorders and cancers.
Join monthly mini-events on these topics
Watch these sessions and more on CONNECTOR
Venture Capital Has Advanced Innovation in China Life Science; It Needs to Do More
At the recent ChinaBio® Partnering Forum, a group of China VCs discussed their very vibrant field: $30 billion in VC investments last year, double the year before. More young companies need support and more capital is available for them. With all the activity, exits are taking place sooner, often before companies have launched a product. But the question remains: how innovative are these companies? Greg Scott, Chairman of ChinaBio®, led the discussion that included representatives of four China VC firms.
Greg B. Scott – Founder and Chairman ChinaBio® Group
Michael Keyoung, MD, PhD – Head of North America C-Bridge Capital
Yuwen Liu – Founding Partner BOHE Angel Fund, Bio2
Hongbo Lu, PhD – Partner Vivo Capital
Victor E. Tong – Partner Decheng Capital
Australian Regenerative Medicine Institute (ARMI) and CCRM Australia Interview
Susanna Ling – Business & Content Development Director EBD Group
Silvio Tiziani – Director, External Strategy and Planning Australian Regenerative Medicine Institute, CEO, CCRM Australia
Therapeutic: Patient-centered drug development in an age of cell and gene therapies
This session will focus on how the role of patients has evolved and is evolving in an era of gene and cell therapies. These new therapies present unique opportunities not only for patient involvement in the development process but pose new challenges, of all stakeholders, around the need for long-term follow up of outcomes from gene therapy. With hundreds of gene and cell therapies in the pipeline, and some now available to patients across global markets, how will we create more uniform approaches for engaging communities and sharing data and information?
Craig Martin – CEO Global Genes
Rodolphe Clerval – CEO Horama
Sheila Mikhail – Co-founder and CEO Asklepios BioPharmaceutical (AskBio)
David Solomon – CEO Pharnext
Learning: Pandemic therapeutics: treating COVID-19 and beyond
While vaccines have taken the limelight, the biotech industry has been working just as hard to develop therapeutic treatments for COVID-19. From innovative new treatments to repurposing well-know drugs, identifying, testing, and manufacturing safe and effective treatments still face the same high bar for approval as before the pandemic, only with the added urgency of immediate need. Hear from some of the companies at the center of this effort about their individual initiatives as well as the broader collaborations established to address the current pandemic and thinking ahead to the next.
Alaric DeArment – Reporter Scrip
Cameron Durrant – Chairman and CEO, Humanigen
Leah Lipsich – VP, Strategic Program Direction, Regeneron
Holger Zimmermann – CEO, AiCuris
Learning: Answering the need: responsive CDMO partnerships
The pandemic has pressurized development, regulatory, manufacturing, and distribution timelines like never before and the biotech industry has responded rapidly to the urgent global needs for vaccines as well as other biopharmaceuticals. In the middle of this pressure-system are the people and companies that have come together to provide the needed solutions to the development and production crunch points. This collaboration close up will take a deep dive into the partnership between Rentschler Biopharma and BioNTech and examine what it took to make this collaboration successful.
Lucie EllisView Profile – Executive Editor, In Vivo, Informa Pharma Intelligence
Oliver Hennig – Senior VP, Operations, BioNTech
Federico Pollano – Senior VP, Global Business Development, Rentschler Biopharma SE
Leading: Impact of COVID-19: Life sciences
What COVID-19 has brought upon the world is a triple inflection of change. Amazing technological advances, regulatory and reimbursement approval, and the profound social imperative for use all come together to make health tech no longer an option, but an imperative